Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
5(83%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
4
67%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Active, not recruiting4
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

completed117%
recruiting117%
active_not_recruiting467%

Recent Activity

5 active trials
Showing 5 of 6
recruitingphase_2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

NCT05601440
active_not_recruitingphase_2

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

NCT04176848
active_not_recruitingphase_2

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

NCT03624543
active_not_recruitingphase_2

Prostate Cancer Biomarker Enrichment and Treatment Selection

NCT03385655
active_not_recruitingphase_1

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

NCT04730258
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05601440Phase 2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting
NCT04176848Phase 2

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Active Not Recruiting
NCT03624543Phase 2

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Active Not Recruiting
NCT03385655Phase 2

Prostate Cancer Biomarker Enrichment and Treatment Selection

Active Not Recruiting
NCT04730258Phase 1

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

Active Not Recruiting
NCT01954316Phase 1

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6